NLS Pharmaceutics AG
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$12,172,029 over the previous period. Total operating expenses were $11,807,063.
Profit Margin
| 2017 | 0 | -6.65M | |
|---|---|---|---|
| 2018 | 0 | -5.14M | |
| 2019 | 0 | -5.44M | |
| 2020 | 0 | -2.86M | |
| 2021 | 0 | -11.94M | |
| 2022 | 0 | -16.49M | |
| 2023 | 0 | -12.17M |
NLSP Income Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 11.40K | 11.40K | 10.05K | 0 | 0 | 0 | 0 |
Gross profit | -11.40K | -11.40K | -10.05K | 0 | 0 | 0 | 0 |
Operating exp. | |||||||
Research and development | 5.90M | 8.97M | 5.91M | 99.58K | 1.70M | 1.43M | 4.32M |
Selling and marketing | 0 | 6.48M | 5.92M | 2.19M | 2.49M | 0 | 0 |
Total operating expenses | 11.80M | 15.47M | 11.85M | 2.29M | 4.19M | 3.44M | 5.76M |
Operating income | -11.80M | -15.48M | -11.86M | -2.29M | -4.19M | -3.44M | -5.76M |
Other income (expenses), net | -364.96K | -1.01M | -85.45K | -562.06K | -1.25M | -629.23K | -890.40K |
Income before tax | -12.17M | -16.49M | -11.94M | -2.86M | -5.44M | -5.14M | -6.65M |
Income tax expense | 0 | 2 | 0 | -2.29K | -4.19K | 1.69M | -5.76K |
Net income | -12.17M | -16.49M | -11.94M | -2.86M | -5.44M | -5.14M | -6.65M |
Earnings per share | |||||||
Basic EPS | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
Diluted EPS | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| Data source | Data source | Data source | Data source |